Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,270 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14664
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
· J Clin Oncol · 2007 · PMID 17538160 · validated civic_curation pubmed
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
· J Clin Oncol · 2006 · PMID 16943533 · validated civic_curation pubmed
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed
p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
· Ann Surg Oncol · 2010 · PMID 19941080 · validated civic_curation pubmed
TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
· Radiother Oncol · 2001 · PMID 11325447 · validated civic_curation pubmed
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
· Clin Cancer Res · 2011 · PMID 21467160 · validated civic_curation pubmed
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
· Eur J Cancer · 2014 · PMID 24915778

Showing 26–50 of 486 publications

← Previous
1
2
3
…
20
Next →

· validated civic_curation

Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma.

· Oral Oncol · 2003 · PMID 12509970 · validated civic_curation pubmed

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

· J Clin Oncol · 2013 · PMID 23182986 · validated civic_curation pubmed

FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.

· Lung Cancer · 2015 · PMID 25433983 · validated civic_curation pubmed

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

· Ann Oncol · 2011 · PMID 21048039 · validated civic_curation pubmed

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

· Eur J Cancer · 2013 · PMID 23265711 · validated civic_curation pubmed

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

· Ann Oncol · 2014 · PMID 24799460 · validated civic_curation pubmed

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.

· Cell Death Dis · 2014 · PMID 24577089 · validated civic_curation pubmed

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

· J Clin Oncol · 2013 · PMID 23816960 · validated civic_curation pubmed

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

· Lancet Oncol · 2014 · PMID 24439929 · validated civic_curation pubmed

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

· Lancet Oncol · 2015 · PMID 25589191 · validated civic_curation pubmed

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

· J Clin Oncol · 2012 · PMID 22493419 · validated civic_curation pubmed

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

· Breast · 2015 · PMID 26255196 · validated civic_curation pubmed

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

· J Clin Oncol · 2010 · PMID 20124187 · validated civic_curation pubmed

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

· Lancet Oncol · 2016 · PMID 26822398 · validated civic_curation pubmed

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

· Cancer Immunol Res · 2014 · PMID 24989892 · validated civic_curation pubmed

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

· Am J Obstet Gynecol · 2005 · PMID 15746676 · validated civic_curation pubmed

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

· N Engl J Med · 2006 · PMID 17192538 · validated civic_curation pubmed